US Science Academies Take on Human-Genome Editing
By Sara Reardon,
Nature
| 05. 18. 2015
[Quotes CGS's Marcy Darnovsky]
The US National Academy of Sciences (NAS) and the National Academy of Medicine (NAM) will launch a major initiative to develop guidelines for editing human genomes, they said on 18 May.
The initiative follows the April announcement that researchers had used a gene-editing system called CRISPR-Cas9 to remove a mutated gene from a human embryo. The work involved a small number of embryos and was only partially successful, but it has sparked wide debate about the ethics of editing human genomes in ways that can be passed on to future generations.
Although researchers and ethicists disagree on whether such research should continue, most agree that its ethical and legal ramifications should be discussed further before a modified embryo is implanted into a human. Many countries ban human germline editing outright. The United States forbids the use of federal funds for such research, although it is legal in most US states.
The academies will hold an international summit this autumn, including scientists, ethicists, patients' groups and others yet to be determined. The academies will also establish a working group to...
Related Articles
By Grace Won, KQED [with CGS' Katie Hasson] | 12.02.2025
In the U.S., it’s illegal to edit genes in human embryos with the intention of creating a genetically engineered baby. But according to the Wall Street Journal, Bay Area startups are focused on just that. It wouldn’t be the first...
By Emma Cieslik, Ms. Magazine | 11.20.2025
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...